Drug firm Lupin on Friday said it has received approval from the US health regulator for generic Hydrocortisone Valerate cream used for relief from inflammation and itching due to various skin conditions.
The company has got approval for its Hydrocortisone Valerate cream USP, 0.2 per cent from the United States Food and Drug Administration (USFDA), Lupin said in a filing to the BSE.
The product is generic version of Sun Pharmaceutical Industries Ltd's Westcort cream in the same strength, it added.
The cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients, Lupin said.
Shares of Lupin Ltd on Friday ended at Rs 729.40 per scrip on the BSE, down 0.67 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app